What is Etolor?
Etolor (Etolor) is a nonsteroidal anti-inflammatory drug (NSAID). Etolor works by reducing hormones that cause inflammation and pain in the body.
Etolor is used to treat mild to moderate pain, osteoarthritis, or rheumatoid arthritis.
Etolor may also be used for purposes not listed in this medication guide.
Etolor indications
Carefully consider the potential benefits and risks of Etolor Extended-Release Tablets and other treatment options before deciding to use Etolor Extended-Release Tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
Etolor Extended-Release Tablets are indicated:
- *
- For relief of signs and symptoms of juvenile arthritis
- *
- For relief of the signs and symptoms of rheumatoid arthritis
- *
- For relief of the signs and symptoms of osteoarthritis
How should I use Etolor?
Use Etolor extended-release tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Etolor extended-release tablets comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Etolor extended-release tablets refilled.
- Take Etolor extended-release tablets by mouth with or without food. It may be taken with food if it upsets your stomach. Taking it with food may not lower the risk of stomach or bowel problems (eg, bleeding, ulcers). Talk with your doctor or pharmacist if you have persistent stomach upset.
- Swallow Etolor extended-release tablets whole. Do not break, crush, or chew before swallowing.
- Take Etolor extended-release tablets with a full glass of water (8 oz/240 mL) as directed by your doctor.
- If you miss a dose of Etolor extended-release tablets and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about the proper use of Etolor extended-release tablets.
Uses of Etolor in details
Etolor is used to relieve painful conditions of the bone, joints and soft tissues such as inflammatory arthritis (rheumatoid arthritis) and advanced osteoarthritis.
Etolor description
Etolor is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
Etolor dosage
Etolor Dosage
Generic name: Etolor
Dosage form: Capsules and Tablets
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Carefully consider the potential benefits and risks of Etolor and other treatment options before deciding to use Etolor. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
After observing the response to initial therapy with Etolor, the dose and frequency should be adjusted to suit an individual patient's needs. As with other NSAIDs, the lowest dose and longest dosing interval should be sought for each patient. Therefore, after observing the response to initial therapy with Etolor, the dose and frequency should be adjusted to suit an individual patient's needs.
Dosage adjustment of Etolor is generally not required in patients with mild to moderate renal impairment. Etolor should be used with caution in such patients, because, as with other NSAIDs, it may further decrease renal function in some patients with impaired renal function.
Analgesia
The recommended total daily dose of Etolor for acute pain is up to 1000 mg, given as 200-400 mg every 6 to 8 hours. Doses of Etolor greater than 1000 mg/day have not been adequately evaluated in well-controlled clinical trials.
Osteoarthritis and Rheumatoid Arthritis
The recommended starting dose of Etolor for the management of the signs and symptoms of osteoarthritis or rheumatoid arthritis is: 300 mg b.i.d., t.i.d., or 400 mg b.i.d., or 500 mg b.i.d. A lower dose of 600 mg/day may suffice for long-term administration. Physicians should be aware that doses above 1000 mg/day have not been adequately evaluated in well-controlled clinical trials.
In chronic conditions, a therapeutic response to therapy with Etolor is sometimes seen within one week of therapy, but most often is observed by two weeks. After a satisfactory response has been achieved, the patient's dose should be reviewed and adjusted as required.
More about Etolor (Etolor)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- En Espanol
- 12 Reviews - Add your own review/rating
Consumer resources
- Etolor
- Etolor (Advanced Reading)
Professional resources
- Etolor (FDA)
- Etolor (AHFS Monograph)
Other formulations
- Etolor XL
Related treatment guides
- Juvenile Rheumatoid Arthritis
- Osteoarthritis
- Pain
- Rheumatoid Arthritis
Etolor interactions
See also:
What other drugs will affect Etolor?
Drug Interactions ACE-inhibitors
Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
Antacids
The concomitant administration of antacids has no apparent effect on the extent of absorption of Etolor. However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak.
Aspirin
When Etolor is administered with aspirin, its protein binding is reduced, although the clearance of free Etolor is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of Etolor and aspirin is not generally recommended because of the potential of increased adverse effects.
Cyclosporine, Digoxin, Methotrexate
Etolor, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increase toxicity. Nephrotoxicity associated with cyclosporine may also be enhanced. Patients receiving these drugs who are given Etolor, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs. NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.
Diuretics
Etolor has no apparent pharmacokinetic interaction when administered with furosemide or hydrochlorothiazide. Nevertheless, clinical studies, as well as post marketing observations have shown that Etolor can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for sings of renal failure, as well as to assure diuretic efficacy.
Glyburide
Etolor has no apparent pharmacokinetic interaction when administered with glyburide.
Lithium
NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
Phenylbutazone
Phenylbutazone causes increase (by about 80%) in the free fraction of Etolor. Although in vivo studies have not been done to see if Etolor clearance is changed by coadministration of phylbutazone, it is not recommended that they be coadministered.
Phenytoin
Etolor has no apparent pharmacokinetic interaction when administered with phenytoin.
Warfarin
The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone. Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Etolor results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin. There was no significant difference in the pharmacodynamic effect of warfarin administered alone and warfarin administered with Etolor as measured by prothrombin time. Thus, concomitant therapy with warfarin and Etolor should not require dosage adjustment of either drug. However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in Etolor-treated patients receiving concomitant warfarin therapy.
Drug/Laboratory Test Interactions
The urine of patients who take Etolor can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of Etolor. Diagnostic dip-stick methodology, used to detect ketone bodies in urine, has resulted in false-positive findings in some patients treated with Etolor. Generally, this phenomenon has not been associated with other clinically significant events. No dose relationship has been observed.
Etolor treatment is associated with a small decrease in serum uric acid levels. In clinical trials, mean decreases of 1 to 2 mg/dL were observed in arthritic patients receiving Etolor (600 mg to 1000 mg/day) after 4 weeks of therapy. These levels then remained stable for up to 1 year of therapy.
Etolor side effects
See also:
What are the possible side effects of Etolor?
A total of 1552 patients were exposed to Etolor Extended-Release Tablets in controlled clinical studies of at least 4 weeks in length and using daily doses in the range of 400 to 1200 mg. In the tabulations below, adverse event rates are generally categorized based on the incidence of events in the first 30 days of treatment with Etolor Extended-Release Tablets. As with other NSAIDs, the cumulative adverse event rates may increase significantly over time with extended therapy.
In patients taking NSAIDs, including Etolor Extended-Release Tablets, the most frequently reported adverse experiences occurring in approximately 1 to 10% of patients are: gastrointestinal experiences including:
| ||
abdominal pain | constipation | diarrhea |
dyspepsia | flatulence | GI ulcers (gastric/duodenal)* |
gross bleeding/perforation* | nausea | vomiting |
other events including: | ||
abnormal renal function* | anemia* | asthenia |
dizziness | edema* | elevated liver enzymes* |
headaches | hypertension | increased bleeding time* |
infection | pharyngitis | pruritus |
rashes | rhinitis | tinnitus* |
Additional NSAID Adverse Experiences Reported Occasionally with NSAIDs or Etolor Extended-Release Tablets Include
Body as a whole - allergic reaction, anaphylactic/anaphylactoid reactions (including shock), chills, fever, sepsis
Cardiovascular system - congestive heart failure, flushing, palpitations, tachycardia, syncope, vasculitis (including necrotizing and allergic)
Digestive system - anorexia, cholestatic hepatitis, cholestatic jaundice, dry mouth, duodenitis, eructation, esophagitis, gastritis, gastric/peptic ulcers, glossitis, hepatic failure, hepatitis, hematemesis, intestinal ulceration, jaundice, liver necrosis, melena, pancreatitis, rectal bleeding, stomatitis
Hemic and lymphatic system - agranulocytosis, ecchymosis, eosinophilia, hemolytic anemia, leukopenia, neutropenia, pancytopenia, purpura, thrombocytopenia
Metabolic and nutritional - hyperglycemia in previously controlled diabetic patients
Nervous system - anxiety, confusion, depression, dream abnormalities, insomnia, nervousness, paresthesia, somnolence, tremors, vertigo
Respiratory system - asthma, dyspnea, pulmonary infiltration with eosinophilia
Skin and appendages - angioedema, cutaneous vasculitis with purpura, erythema multiforme, hyperpigmentation, sweating, urticaria, vesiculobullous rash
Special senses - blurred vision, photophobia, transient visual disturbances
Urogenital system - dysuria, elevated BUN, oliguria/polyuria, proteinuria, renal failure, renal insufficiency, renal papillary necrosis, serum creatinine increase, urinary frequency
Other NSAID Adverse Reactions, Which Occur Rarely Are
Body as a whole - anaphylactic reactions, appetite changes, death
Cardiovascular system - arrhythmia, cerebrovascular accident, hypotension, myocardial infarction
Digestive system - colitis, esophagitis with or without stricture or cardiospasm, thirst, ulcerative stomatitis
Hemic and lymphatic system - aplastic anemia, lymphadenopathy
Metabolic and nutritional - change in weight
Nervous system - coma, convulsions, hallucinations, meningitis
Respiratory - bronchitis, pneumonia, respiratory depression, sinusitis
Skin and appendages - alopecia, exfoliative dermatitis, maculopapular rash, photosensitivity, skin peeling, Stevens-Johnson syndrome, toxic epidermal necrosis
Special senses - conjunctivitis, deafness, hearing impairment, taste perversion
Urogenital system - cystitis, hematuria, interstitial nephritis, leukorrhea, renal calculus, uterine bleeding irregularities
Etolor contraindications
See also:
What is the most important information I should know about Etolor?
This medicine can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use Etolor. Do not use this medicine just before or after having heart bypass surgery (also called coronary artery bypass graft, or CABG).
Seek emergency medical help if you have symptoms of heart or circulation problems, such as chest pain, weakness, shortness of breath, slurred speech, or problems with vision or balance.
This medicine can also increase your risk of serious effects on the stomach or intestines, including bleeding or perforation (forming of a hole). These conditions can be fatal and gastrointestinal effects can occur without warning at any time while you are taking Etolor. Older adults may have an even greater risk of these serious gastrointestinal side effects.
Call your doctor at once if you have symptoms of bleeding in your stomach or intestines. This includes black, bloody, or tarry stools, or coughing up blood or vomit that looks like coffee grounds.
Do not use any other over-the-counter cold, allergy, or pain medication without first asking your doctor or pharmacist. Many medicines available over the counter contain aspirin or other medicines similar to Etolor (such as ibuprofen, ketoprofen, or naproxen). If you take certain products together you may accidentally take too much of this type of medication. Read the label of any other medicine you are using to see if it contains aspirin, ibuprofen, ketoprofen, or naproxen.
Do not drink alcohol while taking Etolor. Alcohol can increase the risk of stomach bleeding caused by Etolor.
Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds). Etolor can make your skin more sensitive to sunlight and sunburn may result.
Active ingredient matches for Etolor:
Etodolac in India.
Unit description / dosage (Manufacturer) | Price, USD |
200 mg x 100's | |
300 mg x 100's | |
400 mg x 100's | |
Etolor 200mg TAB / 100 | |
Etolor 300mg TAB / 100 | |
Etolor 400mg TAB / 100 | |
ETOLOR tab 200 mg x 10's (Intra Labs) | |
ETOLOR tab 300 mg x 10's (Intra Labs) | $ 1.51 |
ETOLOR tab 400 mg x 10's (Intra Labs) | $ 1.63 |
ETOLOR SR tab 600 mg x 10's (Intra Labs) | $ 1.93 |
Etolor 200mg TAB / 100 | |
Etolor 300mg TAB / 100 | |
Etolor 400mg TAB / 100 | |
List of Etolor substitutes (brand and generic names): | |
ETOLIFE | |
Etolife 600mg Tablet ER (Torrent Pharmaceuticals Ltd) | $ 0.12 |
Etolyn (Portugal) | |
Etomax (India) | |
Etomax 400mg FC-TAB / 10 (IPCA (Intima)) | $ 0.59 |
400 mg x 10's (IPCA (Intima)) | $ 0.59 |
ETOMAX 400 MG TABLET 1 strip / 10 tablets each (IPCA (Intima)) | $ 0.63 |
ETOMAX film-coated tab 400 mg x 10's (IPCA (Intima)) | $ 0.59 |
Etomax-ER (India) | |
Etomax-ER 400mg FC-TAB / 10 (IPCA (Intima)) | $ 0.83 |
Etomax-ER 600mg FC-TAB / 10 (IPCA (Intima)) | $ 1.14 |
400 mg x 10's (IPCA (Intima)) | $ 0.83 |
600 mg x 10's (IPCA (Intima)) | $ 1.14 |
ETOMAX-ER film-coated tab 400 mg x 10's (IPCA (Intima)) | $ 0.83 |
ETOMAX-ER film-coated tab 600 mg x 10's (IPCA (Intima)) | $ 1.14 |
Etonox (Thailand) | |
Etonox 200 mg x 10 x 10's (Charoen Bhaesaj Lab) | |
Etonox cap 200 mg 10 x 10's (Charoen Bhaesaj Lab) | |
Etopan 200 (Israel) | |
Etopan 300 (Israel) | |
Etopan 400 (Israel) | |
Etopan 500 (Israel) | |
Etopan XL (United Kingdom) | |
Tablet; Oral; Etodolac 400 mg | |
Tablet; Oral; Etodolac 500 mg | |
Tablet; Oral; Etodolac 600 mg | |
Etopan XL 400 (Israel) | |
Etopan XL 500 (Israel) | |
Etopan XL 600 (Israel) | |
Etopen (Japan) | |
1000 mg x 1's (Solitaire (Euro)) | $ 28.80 |
Etopen 1000mg INJ / 1 (Solitaire (Euro)) | $ 28.80 |
Etopic-MR (India) | |
Etopic-MR Etodolac / SR 400 mg, thiocolchicoside 4 mg. TAB / 10 (Alpic Biotech) | $ 2.05 |
ETOPIC-MR tab 10's (Alpic Biotech) | $ 2.05 |
Etopin (Taiwan) | |
Etopin 200 mg x 100 x 10's (U-Liang) | |
ETORNEXT | |
ETORNEXT 600 MG TABLET ER 1 strip / 10 tablet ers each (Alembic Pharmaceuticals Ltd) | $ 1.52 |
Etornext 600mg Tablet ER (Alembic Pharmaceuticals Ltd) | $ 0.17 |
ETORON | |
ETORON TABLET ER 1 strip / 10 tablet ers each (Ronyd Healthcare Pvt Ltd) | $ 1.30 |
Etoron 600mg Tablet ER (Ronyd Healthcare Pvt Ltd) | $ 0.13 |
ETOSAFE | |
ETOSAFE 600 MG TABLET ER 1 strip / 10 tablet ers each (Wanbury Ltd) | $ 1.63 |
Etosafe 600mg Tablet ER (Wanbury Ltd) | $ 0.16 |
ETOSAINT (India) | |
ETOSAINT SR tab 400 mg (Saint) | |
ETOSWIFT (India) | |
400 mg x 10's (Orchid) | $ 0.66 |
Etoswift 400mg FC-TAB / 10 (Orchid) | $ 0.66 |
ETOSWIFT 300MG TABLET 1 strip / 10 tablets each (Orchid) | $ 0.69 |
ETOSWIFT 400MG TABLET 1 strip / 10 tablets each (Orchid) | $ 0.72 |
ETOSWIFT ER 400MG TABLET 1 strip / 10 tablet ers each (Orchid) | $ 1.45 |
ETOSWIFT ER 500MG TABLET 1 strip / 10 tablet ers each (Orchid) | $ 1.39 |
See 414 substitutes for Etolor |
References
- DailyMed. "ETODOLAC: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "etodolac". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "etodolac". http://www.drugbank.ca/drugs/DB00749 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Etolor are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Etolor. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet2 consumers reported age
Users | % | ||
---|---|---|---|
46-60 | 2 | 100.0% |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology